Company Filing History:
Years Active: 2024
Title: Michael John Giffin: Innovator in Antigen Binding Molecules
Introduction
Michael John Giffin is a notable inventor based in Newbury Park, CA (US). He has made significant contributions to the field of immunology through his innovative work on chimeric receptors and antigen binding molecules. His research focuses on the DLL3 antigen, which has implications for cancer treatment and detection.
Latest Patents
Giffin holds a patent for "Chimeric receptors to DLL3 and methods of use thereof." This patent encompasses antigen binding molecules, chimeric receptors, and engineered immune cells targeting DLL3. The invention also includes vectors, compositions, and methods for treatment and detection utilizing these DLL3 antigen binding molecules and engineered immune cells. He has 1 patent to his name.
Career Highlights
Giffin is currently employed at Amgen Inc., a leading biotechnology company known for its innovative therapies. His work at Amgen has allowed him to collaborate with other talented professionals in the field, further advancing research in immunotherapy.
Collaborations
Some of his notable coworkers include Melissa Thomas and Christopher Murawsky. Their combined expertise contributes to the success of their projects and the advancement of medical science.
Conclusion
Michael John Giffin's contributions to the field of immunology through his patent on DLL3 antigen binding molecules highlight his role as an innovator in biotechnology. His work continues to pave the way for advancements in cancer treatment and detection.